August 7, 2023

🌥️Earnings Overview

On August 3 2023, BIOCRYST PHARMACEUTICALS ($NASDAQ:BCRX) reported its earnings results for the second quarter of FY2023, ending June 30 2023. Total revenue increased by 25.9%, to USD 82.5 million, compared to the same quarter of the previous year. Net income for the quarter was -75.3 million, compared to -58.9 million for the same quarter a year ago.

Share Price

On Thursday, BIOCRYST PHARMACEUTICALS announced its fiscal year 2023 second-quarter earnings, and the news sent the company’s stock up 1.9% from its prior closing price of 7.0. The stock opened at $7.2 and closed at $7.1. This marks a sign of progress for BIOCRYST PHARMACEUTICALS, who have been striving to expand their investments into new areas of research and development. This positive report follows a string of investments in new drug therapies and treatments for rare and infectious diseases, which demonstrates the company’s commitment to innovation.

In addition, BIOCRYST PHARMACEUTICALS has been investing in advanced clinical trials and research, which will serve as potential catalysts for long-term growth. All in all, the results of this quarter are encouraging for BIOCRYST PHARMACEUTICALS and its shareholders. The company has shown continued dedication to expanding its capabilities, which looks promising for the future of the company and its investors alike. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Biocryst Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    306.64 -242.72 -73.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Biocryst Pharmaceuticals. More…

    Operations Investing Financing
    -131.56 -128.24 88.03
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Biocryst Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    529.88 918.6 -1.73
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Biocryst Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    84.0% -43.1%
    FCF Margin ROE ROA
    -43.3% 25.2% -15.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we have conducted a comprehensive analysis of BIOCRYST PHARMACEUTICALS‘ financials. After careful consideration, we have determined that BIOCRYST PHARMACEUTICALS is a medium risk investment in terms of both financial and business aspects. Our analysis of the income sheet, balance sheet, and cashflow statement reveals three distinct risk warnings. To view all the details of this assessment, feel free to become a registered user with us. We believe that having the full picture of an investment’s risk level offers a better decision-making platform for our users. We understand that making investments can be a difficult decision, so we hope our analysis and risk ratings can help you make the best decision for you and your money. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition in the pharmaceutical industry is fierce. BioCryst Pharmaceuticals Inc competes with Royalty Pharma PLC, Novartis AG, and Takeda Pharmaceutical Co Ltd, among others. The company must continually innovate and develop new drugs to stay ahead of its competitors.

    – Royalty Pharma PLC ($NASDAQ:RPRX)

    Royalty Pharma PLC is a global biopharmaceutical company with a market cap of 18.4B as of 2022. The company’s primary focus is on the development and commercialization of innovative therapies to treat serious and life-threatening diseases. Royalty Pharma’s portfolio of products includes treatments for cancer, HIV, rare diseases, and other conditions. The company’s return on equity (ROE) is 11.44%. Royalty Pharma has a strong focus on research and development, and has several products in clinical trials. The company’s pipeline includes potential treatments for a range of conditions, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.

    – Novartis AG ($OTCPK:NVSEF)

    Novartis AG is a large multinational pharmaceutical company headquartered in Basel, Switzerland. The company was formed in 1996 through the merger of Ciba-Geigy and Sandoz, and it has since grown to become one of the world’s largest pharmaceutical companies. Novartis focuses on the discovery, development, and commercialization of innovative medicines and vaccines to treat and prevent a range of diseases. The company’s product portfolio includes treatments for cancer, cardiovascular disease, diabetes, gastrointestinal disorders, infectious diseases, respiratory diseases, and other conditions. Novartis has a market cap of 173.99B as of 2022 and a Return on Equity of 24.65%.

    – Takeda Pharmaceutical Co Ltd ($TSE:4502)

    Takeda Pharmaceutical Co Ltd is a Japanese pharmaceutical company with a market cap of 5.97T as of 2022. The company’s return on equity is 3.5%. Takeda focuses on the development, manufacturing, and marketing of prescription drugs and over-the-counter medications. The company’s products include treatments for cancer, gastrointestinal disorders, and central nervous system disorders.


    BIOCRYST PHARMACEUTICALS had a strong quarter in FY2023 Q2 with total revenue increasing 25.9% compared to the same quarter of the previous year. Net income was down to -75.3 million, but still an improvement from the -58.9 million in the prior year. For investors, this could be a good opportunity to consider making an investment in BIOCRYST PHARMACEUTICALS.

    The revenue growth is a positive sign, and although the net income is still negative, it is going in the right direction. Investors should research further before making any investment decisions.

    Recent Posts

    Leave a Comment